Loading clinical trials...

Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation

NCT06018857•Federico Aucejo

View on ClinicalTrials.gov

Summary

This is a registry study examining patients with HCC undergoing liver transplantation including outcomes and predictors of recurrence

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients (age\>18 years) undergoing Liver transplant for hepatocellular carcinoma

Exclusion Criteria

•Patients under 18 years old
•Patients who do not have hepatocellular carcinoma
•patients who have hepatocellular carcinoma but do not undergo liver transplantation

Locations (2)

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Ohio State University

Columbus, Ohio, United States

Key Dates

Start Date

May 11, 2017

Primary Completion Date

December 1, 2028

Completion Date

December 1, 2028

Last Updated

March 6, 2026

Enrollment

1,000

ESTIMATED participants

Conditions

Hepatocellular Carcinoma

Early Detection of Liver Cancer by QUS

NCT06345508

Hepatocellular CarcinomaLiver Cancer

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation

Inclusion Criteria

Exclusion Criteria

Early Detection of Liver Cancer by QUS

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)